XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)
$ in Thousands
3 Months Ended 6 Months Ended
Oct. 07, 2020
USD ($)
Obligation
Bundle
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Jan. 31, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenues   $ 151,805 $ 32,811 $ 179,244 $ 54,113    
Contract liabilities, current   97,869   97,869   $ 111,055  
Deferred revenue, net of current portion   89,754   89,754   $ 131,495  
Takeda License Agreement | License and Co-Funding Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 07, 2020            
Ratio of Profit Sharing Structure for United States Commercialization 50/50 profit sharing            
Cash received as due under collaboration agreement             $ 300,000
Number of distinct bundle | Bundle 1            
Number of distinct performance obligations | Obligation 1            
Initial transaction price $ 300,000            
Revenues   20,800 $ 25,400 41,600 $ 33,600    
Contract assets   0   0      
Takeda License Agreement | License and Co-Funding Agreement | Deferred Revenue              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Contract liabilities, current   77,900   77,900      
Deferred revenue, net of current portion   89,800   89,800      
Takeda License Agreement | License and Co-Funding Agreement | Accrued Expenses              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Contract liabilities, current   $ 5,000   $ 5,000      
Takeda License Agreement | Minimum [Member] | License and Co-Funding Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Percentage of eligible to receive tiered royalties on net sales 20.00%            
Takeda License Agreement | Maximum | License and Co-Funding Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Percentage of eligible to receive tiered royalties on net sales 25.00%            
Development regulatory and sales milestones payments             $ 740,000